OTR3

OTR3® is a French biotech company that has developed a new class of therapeutic agents used for skin and corneal healing. The therapeutic approach, called "Matrix therapy" is based on RGTA® (ReGeneraTing Agents), engineered biodegradable sugar-based nano-polymers, mimicking heparan-sulfates. After an injury, RGTA® target the wound, replace the degradated heparan-sulfates, bind to the proteins and growth factors and protect the matrix proteins from degradation. They restore the scaffold organization and the micro-environment of the cells allowing the tissue to rebuild. OTR3 has placed on the market medical devices indicated for the treatment of hard to heal chronic cutaneous ulcers and corneal ulcers. OTR3's Pipeline include innovative therapeutic products for ischemic stroke (Project awarded a H2020 SME Instrument grant), Acute respiratory distress syndrome (ARDS) and chronic ulcer for epidermolysis bullosa (Project awarded a PIA Leader Innov'Up grant).